Recombinant proteins

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

Retrieved on:

Tuesday, June 29, 2021

Branches of biology, Peptide hormones, Endocrine system, Diabetes, Biology, Recombinant proteins, Anti-diabetic drugs, Pramlintide, Insulin analog, Insulin pump, Amylin, Insulin

So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.

Key Points:

So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.
Adocia has developed two products, M1Pram in pen for Multiple Daily Injection, currently in Phase 2, and now BC LisPram for insulin pump delivery.
BioChaperone Lispro Pramlintide (BC LisPram) is a fixed combination of two approved hormones analogs, the insulin analog lispro and the amylin analog pramlintide.
Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes.

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

Retrieved on:

Tuesday, June 29, 2021

Branches of biology, Peptide hormones, Endocrine system, Diabetes, Biology, Recombinant proteins, Anti-diabetic drugs, Pramlintide, Insulin analog, Insulin pump, Amylin, Insulin

So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.

Key Points:

So, we are very excited to study BC LisPram, which allows the use of only one pump to deliver both hormones, declared Dr. Ahmad Haidar.
Adocia has developed two products, M1Pram in pen for Multiple Daily Injection, currently in Phase 2, and now BC LisPram for insulin pump delivery.
BioChaperone Lispro Pramlintide (BC LisPram) is a fixed combination of two approved hormones analogs, the insulin analog lispro and the amylin analog pramlintide.
Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on development of a hydrogel scaffold for use in people with type 1 diabetes.

Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions And Weight Loss

Retrieved on:

Tuesday, June 29, 2021

Branches of biology, Peptide hormones, Clinical medicine, Medicine, Recombinant proteins, Diabetes, Insulin, Semaglutide, Type 2 diabetes, Diabetes medication, Insulin analog

Tirzepatide is under development and in phase three of clinical trials for the treatment of type 2 diabetes.

Key Points:

Tirzepatide is under development and in phase three of clinical trials for the treatment of type 2 diabetes.
In SURPASS-2, all three tirzepatide doses delivered superior A1C and body weight reductions from baseline compared to semaglutide.
In SURPASS-3, all three tirzepatide doses delivered superior A1C and body weight reductions from baseline compared to titrated insulin degludec.
In SURPASS-5, all three tirzepatide doses delivered superior A1C reductions and weight reductions compared to placebo both added to titrated insulin glargine.

Walmart Revolutionizes Insulin Access & Affordability for Patients With Diabetes With the Launch of the First and Only Private Brand Analog Insulin

Retrieved on:

Tuesday, June 29, 2021

Retail, Health, Diabetes, Other Retail, Discount, Variety, Department Stores, Pharmaceutical, Branches of biology, Peptide hormones, Recombinant proteins, Endocrine system, Hormones, Diabetes, Insulin, Diabetes management

Walmart announced the launch of the first-ever private brand analog insulin, which will revolutionize the access and affordability to diabetes care by offering customers a significant price savings without compromising quality.

Key Points:

Walmart announced the launch of the first-ever private brand analog insulin, which will revolutionize the access and affordability to diabetes care by offering customers a significant price savings without compromising quality.
Available exclusively through Walmarts private ReliOn brand, the new offering includes analog insulin vials ($72.88) and FlexPen ($85.88).
ReliOn NovoLog is a rapid-acting insulin analog used to control high blood sugar in adults and children with diabetes.
Walmart is a destination for affordable diabetes resources, including blood glucose monitors, lancets and other diabetes management essentials in the ReliOn portfolio.

Global Insulin Pens Market 2021-2025: Increasing Product Launches & Growing Prevalence of Diabetes Cases - ResearchAndMarkets.com

Retrieved on:

Monday, June 28, 2021

Pharmaceutical, Health, Medical devices, Clinical medicine, Organ systems, Branches of biology, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Type 1 diabetes, Injector pen, Market analysis

The insulin pens market is poised to grow by $3.43 billion during 2021-2025, progressing at a CAGR of about 8%

Key Points:

The insulin pens market is poised to grow by $3.43 billion during 2021-2025, progressing at a CAGR of about 8%
The report on the insulin pens market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The market is driven by the growing prevalence of diabetes cases and rising government initiatives to prevent diabetes in developed countries.
This study identifies the increasing product launches as one of the prime reasons driving the insulin pens market growth during the next few years.
Also, the insulin pens market analysis report includes information on upcoming trends and challenges that will influence market growth.

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

Retrieved on:

Thursday, June 17, 2021

Biotechnology, FDA, Health, Pharmaceutical, Oncology, Health care, Life sciences, Drugs, Amgen, Recombinant proteins, Biotechnology, Biosimilar, Amneal Pharmaceuticals, Filgrastim, Bevacizumab, Pegfilgrastim

Bevacizumab is the biosimilar version of Avastin and when approved will be marketed under the proprietary name AlymsysTM.

Key Points:

Bevacizumab is the biosimilar version of Avastin and when approved will be marketed under the proprietary name AlymsysTM.
Amneal and mAbxience believe that the data supports the biosimilarity of its AlymsysTM product to Avastin.
The FDAs acceptance of our BLA for Bevacizumab is a significant milestone in our journey to become an important player in biosimilars, stated Chirag and Chintu Patel, Co-Chief Executive Officers.
As previously announced, the Company expects its initial biosimilar portfolio will include Filgrastim (biosimilar for Neupogen), Pegfilgrastim (biosimilar for Neulasta) and Bevacizumab (biosimilar for Avastin).

Amalgam Rx™ Receives CE Mark for Basal Insulin Titration

Retrieved on:

Wednesday, June 16, 2021

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.

Key Points:

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformit Europenne (CE) Mark for its insulin titration application, iSage Rx and its white-labeled variants.
View the full release here: https://www.businesswire.com/news/home/20210616005524/en/
Amalgam Rx Receives CE Mark for Basal Insulin Titration (Graphic: Business Wire)
With this CE Mark, iSage Rxs capacity to support the titration of all basal insulins and enable connectivity to the leading Bluetooth-enabled blood glucose meters from Roche, Lifescan, and Ascensia, is now cleared for the European market.
In early clinical studies, the iSage Rx app has demonstrated the ability to improve patients glucose levels by helping them reach the appropriate level of basal insulin.
Amalgam is the manufacturer of the iSage Rx app and white-labeled variants, the first prescription-only mobile application for the automated titration of all brands of basal insulin to receive market authorization in the United States, EU, and Brazil.

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced

Retrieved on:

Tuesday, June 8, 2021

Branches of biology, Amgen, Growth factors, Recombinant proteins, Cytokines, Granulocyte colony-stimulating factor, Pegfilgrastim, Filgrastim, Plinabulin, Neutrophil, Myelocyte

Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).

Key Points:

Compared to pegfilgrastim alone (n=110), the plinabulin and pegfilgrastim combination (n=111) showed decreased production of immature neutrophil band (p=0.0012), and decreased promyelocytes and myelocyte production (p=0.0488).
Immature neutrophil band and promyelocytes and myelocytes are less functional defending against infection and have potentially deleterious immune suppression effects.
The Company has submitted New Drug Applications (NDA) for plinabulin in combination with pegfilgrastim as a treatment for the prevention of CIN for review in both the U.S. and China.
Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Onco

Retrieved on:

Monday, June 7, 2021

Branches of biology, Clinical medicine, Medicine, Amgen, Growth factors, Recombinant proteins, Oncology, Granulocyte colony-stimulating factor, Plinabulin, Neutropenia, Pegfilgrastim, Filgrastim

Chemotherapy-induced neutropenia continues to represent an unmet medical need despite the use of G-CSF, thus novel approaches are needed.

Key Points:

Chemotherapy-induced neutropenia continues to represent an unmet medical need despite the use of G-CSF, thus novel approaches are needed.
The poster, titled Chemotherapy Induced Profound Neutropenia (PN) in Patients (pt) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim (Peg) Combination versus (vs) Peg Alone.
This is the first study to quantify physical wellbeing (pain and energy levels) of patients receiving plinabulin in combination with pegfilgrastim compared to pegfilgrastim alone.
We are very pleased to announce new positive clinical outcome data from the PROTECTIVE-2 Phase 3 program.

Worldwide Rapid Acting Insulin Industry to 2027 - Sedentary and Unhealthy Lifestyles are Driving Growth - ResearchAndMarkets.com

Retrieved on:

Monday, May 31, 2021

Health, Pharmaceutical, Clinical medicine, Branches of biology, Endocrine system, Peptide hormones, Recombinant proteins, Diabetes, Insulin, Hypoglycemia, Insulin analog, Insulin pump

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027.

Key Points:

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027.
In addition, rapid acting insulin act very quickly, they can lead to an increased chance of hypoglycemia.
Some of the rapid acting insulin available in the market include Fiasp, Humalog, NovoRapid, Apidra and others.
However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry.